CITE-Seq analysis of FACS-sorted live human CD45+ cells isolated from the ears of huNOG-EXL mice in a model of atopic dermatitis

CD200R is an immune checkpoint receptor of the IgG family that is primarily expressed on cells of the myeloid lineage. In vivo studies with knockout mice of either the receptor or its ligand, CD200, have demonstrated that it is an inhibitory receptor capable of negatively regulating immune responses. Previous work using agonistic antibodies to mouse CD200R showed inhibition of mast cell activation in multiple preclinical models of autoimmune diseases. We developed an agonistic antibody to the human CD200 receptor to downregulate the immune system human inflammatory conditions. Ucenprubart, is a humanized IgG4 monoclonal antibody that binds and agonizes human CD200R to suppress cellular activity in CD200R-expressing cells.The antibody was engineered to have desired properties for agonism and cross-reactivity to cyno CD200R. In vivo the antibody demonstrated efficacy in a humanized mouse model of contact hypersensitivity as well as passive cutaneous anaphylaxis in cynomolgus monkeys. Overall design: CITE-Seq analysis of FACS-sorted live human CD45+ cells isolated from the ears of huNOG-EXL mice one day after the third oxazolone challenge in a model of atopic dermatitis. Mice were previously treated with CD200R agonist mAb (Ucenprubart), dupilumab, or an isotype control mAb (two biological replicates per treatment group).